Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 26;12(13):4287.
doi: 10.3390/jcm12134287.

Lung Transplant Recipients and COVID-19: Report of Two Cases

Affiliations
Review

Lung Transplant Recipients and COVID-19: Report of Two Cases

Filippo Antonacci et al. J Clin Med. .

Abstract

Although the WHO has declared the end of the pandemic emergency, COVID-19 still poses a threat to immunocompromised patients. The COVID-19 pandemic has spread throughout the world over the last two years, causing a significant number of deaths. After three years, SARS-CoV-2 has lost its initial lethality but has shown a significantly worse prognosis for immunocompromised patients, especially those who have undergone lung transplantation, compared with the general population. This paper presents two compelling case studies that highlight the complex challenges of COVID-19 infection in lung transplant recipients. The first case involves a patient who received a bilateral lung transplant for pulmonary artery hypertension in 2009, followed by a kidney transplant in 2022. Surprisingly, despite an initially favorable clinical course after contracting COVID-19, the patient deteriorated rapidly and died within a few days due to extensive lung involvement. This case highlights the unpredictable nature of COVID-19 and its potentially devastating impact on lung transplant recipients. The second case involves a patient who underwent bilateral lung transplantation five years earlier for chronic obstructive pulmonary disease (COPD). This individual also contracted COVID-19 and had pre-existing complications, including chronic lung allograft rejection (CLAD) and diffuse bronchial stenosis. Following viral infection, the patient's clinical condition deteriorated rapidly, with worsening bronchial stenosis. This case highlights the ability of COVID-19 to exacerbate pre-existing pulmonary complications in transplant recipients. These cases highlight the urgent need for increased vigilance and tailored management strategies when dealing with COVID-19 in lung transplant recipients. The unpredictable and detrimental course of the disease observed in these patients highlights the importance of implementing stringent preventive measures, such as vaccination and strict adherence to infection control protocols, in this vulnerable population. Further research is essential to gain a full understanding of the unique dynamics of COVID-19 in lung transplant recipients and to develop targeted interventions to improve their outcomes.

Keywords: COVID-19; chronic lung allograft rejection; lung transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Case #1. Chest CT in December 2022 (left) and January 2023 (right). In January 2023, we observed an increased lung parenchymal involvement compared with December 2022.
Figure 2
Figure 2
Case #2. Chest CT in March 2021 (left) and February 2023 (right). The lung parenchymal involvement worsened in February 2023, compared with March 2021, with the development of pneumonia and pleural effusion.

Similar articles

Cited by

References

    1. Tsatsakis A., Calina D., Falzone L., Petrakis D., Mitrut R., Siokas V., Pennisi M., Lanza G., Libra M., Doukas S.G., et al. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem. Toxicol. 2020;146:111769. doi: 10.1016/j.fct.2020.111769. - DOI - PMC - PubMed
    1. Siddiqi H.K., Mehra M.R. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J. Heart Lung Transplant. 2020;39:405–407. doi: 10.1016/j.healun.2020.03.012. - DOI - PMC - PubMed
    1. Schaffrath J., Brummer C., Wolff D., Holtick U., Kröger N., Bornhäuser M., Kraus S., Hilgendorf I., Blau I.W., Penack O., et al. High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. Transplant. Cell. Ther. 2022;28:337.e1–337.e10. doi: 10.1016/j.jtct.2022.03.010. - DOI - PMC - PubMed
    1. Messika J., Eloy P., Roux A., Hirschi S., Nieves A., Le Pavec J., Sénéchal A., Saint Raymond C., Carlier N., Demant X., et al. COVID-19 in Lung Transplant Recipients. Transplantation. 2021;105:177–186. doi: 10.1097/TP.0000000000003508. - DOI - PubMed
    1. Kamp J.C., Hinrichs J.B., Fuge J., Ewen R., Gottlieb J. COVID-19 in lung transplant recipients-Risk prediction and outcomes. PLoS ONE. 2021;16:e0257807. doi: 10.1371/journal.pone.0257807. - DOI - PMC - PubMed

LinkOut - more resources